July 3rd 2024
Clinical trial for BI 3034701 is expected to evaluate the safety, tolerability, and pharmacokinetics in healthy men and overweight or obese individuals aged 18-55 years old.
Three-Pronged Approach to Optimizing Trial Monitoring
Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.